The focus for the hepatology reasearch group is clinical epidemiology, clinical trials and diagnostic modalities in chronic liver disease, including cirrhosis and its complications. We aim to include the main patient groups within general hepatology (including viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, and autoimmune liver diseases) and conduct clinically relevant research through observational studies and randomized controlled trials. We collaborate with national and international research networks, including Centre for Elimination of Hepatitis C (SELIHEP), Chronic Liver Failure Consortium (CLIF), Inflammatory bowel disease research group (IBSEN), the National Institute of Public Health (NIPH), and The Bergen Research Group for UltraSound in GastroEnterology (BRUSE).

• The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis (ESSENCE): Industry-initiated international phase 3 study
• Opportunistic treatment of hepatitis C infection (OPPORTUNI-C): Investigator-initiated multi-centre pragmatic cluster randomized trial
• Low-threshold models of hepatitis C care for people who inject drugs: A series of observational cohort studies
• Epidemiology and surveillance of hepatocellular carcinoma: Retrospective studies
• Outcomes of treatment with Transjugular Intrahepatic Portosystemic Shunts (TIPS): Retrospective cohort study
• Novel non-invasive methods for detection of liver fibrosis, inflammation and steatosis: Prospective observational study